Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navoximod + Atezolizumab in Advanced Solid Tumors
NCT02471846Phase 1Completed
- Sponsor
- Genentech
- Start
- Jul 2015
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of navoximod in solid tumor (6 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants With Dose-limiting Toxicities at 21 days and Percentage of Participants With Adverse Events at 3 years. Started Jul 2015; status: completed.
02
Drugs
navoximod
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02471846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02471846.